Hepion Pharmaceuticals Files 2023 Annual Report Amendment

TL;DR

Hepion Pharma (HEPN) filed its amended 2023 10-K. Check for updates.

AI Summary

Hepion Pharmaceuticals, Inc. filed an amendment (10-K/A) to its annual report for the year ended December 31, 2023. The company, formerly known as ContraVir Pharmaceuticals, Inc., is based in Edison, NJ, and operates in the pharmaceutical preparations sector. This filing provides updated information for the period ending December 31, 2023.

Why It Matters

This amendment to the annual report provides updated financial and operational information for Hepion Pharmaceuticals, Inc., which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Hepion is subject to the inherent risks of drug development, regulatory approvals, and market competition.

Key Numbers

• 2023 — Fiscal Year End (The annual report covers the period ending December 31, 2023.)
• 46-2783806 — IRS Number (Company's IRS identification number.)

Key Players & Entities

• Hepion Pharmaceuticals, Inc. (company) — Registrant
• ContraVir Pharmaceuticals, Inc. (company) — Former company name
• December 31, 2023 (date) — Fiscal year end
• Edison, NJ (location) — Business address
• 001-36856 (other) — SEC file number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share The Nasdaq Capital Market
• $50 million — nce 2006, has led or "co-led" more than $50 million in research funding. Honors include an
• $400,000 — r. Cavan's current base compensation is $400,000 per year. Mr. Cavan is eligible to rece

Filing Documents

• form10-ka.htm (10-K/A) — 222KB
• ex31-1.htm (EX-31.1) — 16KB
• ex31-2.htm (EX-31.2) — 15KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• form10-ka_001.jpg (GRAPHIC) — 2KB
• 0001493152-24-025007.txt ( ) — 516KB
• hepa-20231231.xsd (EX-101.SCH) — 3KB
• hepa-20231231_lab.xml (EX-101.LAB) — 35KB
• hepa-20231231_pre.xml (EX-101.PRE) — 23KB
• form10-ka_htm.xml (XML) — 7KB

Executive Compensation

Executive Compensation 7 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 9 Item 13. Certain Relationships and Related Transactions, and Director Independence 9 Item 14. Principal Accounting Fees and Services 9 PART IV Item 15. Exhibits and Financial Statement Schedules 10

SIGNATURES

SIGNATURES 12 2 PART III Item 10. Directors, Executive Officers and Corporate Governance. Executive Officers and Directors Set forth below is certain information with respect to the individuals who are our directors and executive officers as of June 20, 2024: Name Age Position(s) John Cavan 65 Interim Chief Executive Officer and Chief Financial Officer John P. Brancaccio 76 Executive Chairman Timothy Block, Ph.D. 68 Director Kaouthar Lbiati, M.D. 45 Director Michael Purcell 67 Director John Cavan has been our interim Chief Executive Officer since December 2023 and Chief Financial Officer since March 2016. Previously, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products (an Ashland Company) and Nestl U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University. John P. Brancaccio, a retired CPA, has served as Executive Chairman since March 2024 and a director of our Company since May 15, 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director

Executive Compensation

Executive Compensation. Summary Compensation Table The following table contains compensation information for our Chief Executive Officer and certain other executives who were the most highly compensated executive officers for the years ended December 31, 2023 and 2022. Non-equity incentive plan Options compensation ($) Name & Principal position Year Salary ($) granted ($) (1) Total ($) Dr. Robert Foster (2) 2023 506,282 0 0 506,282 Former Chief Executive Officer 2022 533,333 0 192,500 725,833 John Cavan 2023 400,000 0 0 400,000 Interim Chief Executive Officer and Chief Financial Officer 2022 383,333 0 112,000 495,333 Dr. Todd Hobbs (3) 2023 318,750 0 0 318,750 Former Chief Medical Officer 2022 425,000 0 153,000 578,000 (1) Represents cash bonus payments earned based upon the achievement of corporate objectives established by our Compensation Committee for performance during the years ended December 31, 2023 and 2022, as further described above in " Variable Annual Cash Bonus Structure and Payouts ." (2) Dr. Foster left the Company in December 2023. (3) Dr. Hobbs left the Company in August 2023. Employment Agreements On October 4, 2019, we entered into an Executive Agreement (the " Cavan Agreement ") with John Cavan, our interim Chief Executive Officer and Chief Financial Officer. The term of the Cavan Agreement commenced on October 4, 2019 and continued until October 4, 2022, following which time the Cavan Agreement will be automatically renewed for successive one year periods at the end of each term, unless either party delivers written notice to the other party of their intent to not renew the Cavan Agreement. Pursuant to the Cavan Agreement, Mr. Cavan's current base compensation is $400,000 per year. Mr. Cavan is eligible to receive a cash bonus of up to 40% of his base salary per year based on meeting certain performance objectives and bonus criteria. If Mr. Cavan's employment is terminat

View Full Filing

View this 10-K/A filing on SEC EDGAR